Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

Xia et al. report the development and optimization of a high-throughput screening platform to systematically determine cancer cell sensitivity to pharmacological and genetic perturbations, BMS-PRISM, based on PRISM and high-throughput CRISPR/Cas9 loss-of-function screen technologies using cell line...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yifeng Xia, Xiaodong Ji, In Sock Jang, Christine Surka, Christy Hsu, Kai Wang, Mark Rolfe, Neil Bence, Gang Lu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/4d8d29c70bdc4a77a7632fc27bcf2dfd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!